Par Pharmaceutical Cos RSS Feed | Nachrichten - www.finanzen.net

Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial

WOODCLIFF LAKE, N.J., May 29 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. today announced that its development partner, Alfacell Corporation reported that the preliminary ...

Par Pharmaceutical Reports First Quarter 2008 Results

WOODCLIFF LAKE, N.J., May 8 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today reported results for the first quarter ended March 29, 2008.Par reported total revenues of $154.9 million and net income of $2.6 million, or $0.08 per diluted ...

Par Pharmaceutical Acquires Spectrum Pharmaceutical's Interest In Sumatriptan Injection

WOODCLIFF LAKE, N.J., May 7 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today announced that it amended its agreement with Spectrum Pharmaceuticals, Inc. for $20 million in cash to increase its share of profits from the generic versions ...

Par Pharmaceutical to Host First Quarter 2008 Earnings Conference Call on May 9 at 9:00 AM

WOODCLIFF LAKE, N.J., May 5 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. announced today that it will host a conference call and live webcast on Friday, May 9, 2008 at 9:00 am ET to review results for the first quarter ended March 29, ...

ANALYSE: Needham best�tigt Yahoo! vor Zahlen mit 'Hold'

NEW YORK (dpa-AFX) - Needham Co hat die Aktie von Yahoo! vor Zahlen für das erste Geschäftsquartal mit "Hold" bestätigt. Die Ziele des Managements ...

Strativa Pharmaceuticals Announces Phase III Results for Loramyc(R) to Treat Oropharyngeal Candidiasis

WOODCLIFF LAKE, N.J., April 21 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of Par Pharmaceutical Companies, Inc. today announced that its development partner, BioAlliance Pharma reported preliminary, top-line ...

Par Pharmaceutical Reports Fourth Quarter and Full Year 2007 Results

WOODCLIFF LAKE, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. today reported fourth quarter and full year 2007 results ended December 31, 2007.Fourth Quarter and 2007 ResultsFor the fourth quarter ended December 31, 2007, ...

Strativa Pharmaceuticals, a Division of Par Pharmaceutical, Announces the Discontinuation of the Development Program for Pafuramidine

WOODCLIFF LAKE, N.J., Feb. 25 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. today announced that its development partner, Immtech Pharmaceuticals, ...

Strativa Pharmaceuticals Acquires Commercialization Rights to Onconase(R) from Alfacell Corporation

WOODCLIFF LAKE, N.J., Jan. 15 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. and Alfacell Corporation today announced that they have entered into ...

Alfacell Corporation Licenses ONCONASE(R) U.S. Commercial Rights to Strativa Pharmaceuticals

SOMERSET, N.J., Jan. 15 /PRNewswire-FirstCall/ -- Alfacell Corporation today announced that it has entered into a license agreement with Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, ...